Related Experiment Video

Updated: Nov 26, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives

Nicole Brighi1, Vincenza Conteduca1, Cristian Lolli1

  • 1Department of Medical Oncology, Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" (IRST) IRCCS, Meldola, Italy.

Critical Reviews in Oncology/Hematology
|December 14, 2020
PubMed

Insights

New CDK4/6 inhibitors show promise for prostate cancer (PC) treatment. Research is exploring their role in various stages and forms of PC, aiming to improve outcomes for this common male mortality cause.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer (PC) remains a significant cause of male mortality despite advances in treatment.
  • Translational research is crucial for understanding PC carcinogenesis, progression, and treatment resistance.
  • The cyclin-dependent kinases (CDK) pathway is a key regulator of the PC cell cycle.

Purpose of the Study:

  • To review current knowledge on the CDK pathway and CDK inhibitors in prostate cancer.
  • To discuss the biological rationale for using CDK inhibitors in PC.
  • To summarize the status of clinical trials evaluating CDK inhibitors for PC.

Main Methods:

  • Literature review of current knowledge on CDK pathway and inhibitors.
  • Analysis of the biological rationale for CDK inhibitor use in PC.
  • Overview of ongoing clinical trials for CDK inhibitors in various PC states.

Main Results:

  • CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib) are under investigation for PC.
  • These inhibitors target the cell cycle, offering a promising therapeutic strategy.
  • Clinical trials are evaluating their efficacy in early, advanced, hormone-sensitive, and castration-resistant PC.

Conclusions:

  • CDK4/6 inhibitors represent a promising therapeutic avenue for prostate cancer.
  • Ongoing clinical trials will determine their role in improving outcomes across different PC stages.
  • Precision oncology approaches may aid in selecting appropriate patients for CDK inhibitor therapy.
Keywords:
CDK signalingCastration resistanceCastration-sensitiveCyclin D1Drug developmentRandomized controlled trial

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.9K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.0K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K